Cargando…
Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo
OBJECTIVE: To evaluate the pharmacological properties of JTE-052, a novel Janus kinase (JAK) inhibitor. METHODS: The JAK inhibitory activity of JTE-052 was evaluated using recombinant human enzymes. The inhibitory effects on cytokine signaling pathways were evaluated using primary human inflammatory...
Autores principales: | Tanimoto, Atsuo, Ogawa, Yoshihiro, Oki, Chika, Kimoto, Yukari, Nozawa, Keisuke, Amano, Wataru, Noji, Satoru, Shiozaki, Makoto, Matsuo, Akira, Shinozaki, Yuichi, Matsushita, Mutsuyoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Basel
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286029/ https://www.ncbi.nlm.nih.gov/pubmed/25387665 http://dx.doi.org/10.1007/s00011-014-0782-9 |
Ejemplares similares
-
Improvement of spontaneous locomotor activity with JAK inhibition by JTE-052 in rat adjuvant-induced arthritis
por: Tanimoto, Atsuo, et al.
Publicado: (2015) -
JTE-852, a novel spleen tyrosine kinase inhibitor, blocks antigen-induced allergic reactions in rats
por: KATO, Toshinobu, et al.
Publicado: (2018) -
Step-Double-Zone-JTE for SiC Devices with Increased Tolerance to JTE Dose and Surface Charges
por: Huang, Yifei, et al.
Publicado: (2018) -
Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE‐052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis
por: Nakagawa, Hidemi, et al.
Publicado: (2018) -
JTE: first Impact Factor of 2.683
por: Knowles, Jonathan, et al.
Publicado: (2018)